「th」の検索結果
184件：86～90件目を表示
-
千寿製薬株式会社
e 1, 2026 Launch of Distribution of 3in1Smart and SPM-700（PDF） April 6, 2026 Launch of “Avarept® Ophthalmic Suspension 0.3%” in Japan, A Novel Treatment of Dry Eye Disease through TRPV1 Inhibition（PDF...
http://www.senju.co.jp/english/ -
harmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Shuhei Yoshida) today announces that it has received approval for the marketing of “Mytear Lumify” (OTC drug requiring instruction b...
https://www.senju.co.jp/system/files/content_news/2024-08/ENG_20240903_0.pdf -
h 7, 2025 General Announcement Senju Pharmaceutical Co., Ltd. Announcement of Licensing Agreement with Brill International Senju Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President: Mr. Sh...
https://www.senju.co.jp/system/files/content_news/2025-03/ENG_20250307.pdf -
お知らせ | 千寿製薬株式会社
https://www.senju.co.jp/english/news/javascipt: void(0); -
ida Pharmaceutical Co., Ltd. Obtained manufacturing and marketing approval in Japan for Avarept® Ophthalmic suspension 0.3%, a novel treatment of Dry Eye Disease through Transient Receptor Potential c...
https://www.senju.co.jp/system/files/content_news/2025-12/ENG_20251222.pdf